Coronary heart disease, Medtronic-Fbf S. Pietro Roma agreement based on clinical outcome

First agreement in Italy based on the value in the treatment of patients with coronary heart disease between Medtronic, a leading company in medical technologies and solutions, and the Fatebenefratelli San Pietro Hospital in Rome aimed at early discharge after coronary angioplasty. This is the first example in our country – a company note reports – of a risk-sharing program aimed at encouraging the early discharge of patients undergoing coronary angioplasty. This is an agreement with one of the main national reference centers in the management of patients with coronary artery disease, the Fatebenefratelli San Pietro hospital in Rome, which has always equipped itself with cutting-edge technologies and innovative approaches capable of maximizing outcomes and the experience of care of its patients. Thanks to the agreement of Value Based procurement – details the note – Medtronic shares with the hospital the risk of a possible failure in cases in which patients, initially eligible for an optimized hospitalization, present complications such as not to allow early discharge. Medtronic, to support the structure in the optimized and increasingly remote management of the patient, provides the center with an IT platform for the collection and measurement of outcomes (Ohcs – One hospital clinical service) with to collect evidence of the efficacy and safety of the procedure and an App for measuring Patients reported outc omes (MySTENT App) which, up to 7 days after discharge, automatically and real-time feeds the platform to which the hospital has access, allowing remote monitoring of the quality of life and perception of patients as protagonists of an optimized path . The evaluation of clinical outcomes is therefore an essential step to give the right value to therapies with a high technological impact. “A further agreement based on the clinical outcome that follows Medtronic’s other experiences in the field of chronic pain and atrial fibrillation, with to contribute to the transformation towards value-based healthcare, explains Guido Beccagutti – Value & Access Director Western Europe – placing the patient and their needs at the center of a healthcare system that today pays and finances by volume of services. The goal is to contribute to a new model of access and financing of technological innovation, in which the company shares direct responsibility for the outcomes and costs measured in clinical practice with the provider. We want to contribute to the creation of a new ecosystem with which to guarantee the best treatments at a sustainable cost “.” The initiative that sees us as protagonists – comments Francesco Monti, Uoc Cardiology Director of the Fatebenefratelli San Pietro hospital in Rome – aims to really look at the patient by leveraging a new concept of health, understood as well-being – guaranteed not only by the quality of the services provided but also by an optimized and efficient treatment path. An early discharge after coronary angioplasty is able to maximize the quality of life and the perception of patients with regard to their own state of health, as well as responding to the needs made clear by the pandemic situation still underway “. “All this – continues Monti – is possible thanks to the technological innovation available, to a cutting-edge medical-scientific staff and to a very efficient hospital organization. The real challenge is to be able to involve and motivate all the professionals involved in the patient care path (doctors, administrators and companies), to offer a health product that is truly centered on the patient and his needs “.